Articles with public access mandates - Elliot StieglitzLearn more
Not available anywhere: 2
Germline RRAS2 mutations are not associated with Noonan syndrome
JJ Ceremsak, A Yu, E Esquivel, C Lissewski, M Zenker, ML Loh, ...
Journal of Medical Genetics 53 (11), 728-728, 2016
Mandates: German Research Foundation
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group
E Stieglitz, AG Lee, SP Angus, C Davis, DA Barkauskas, D Hall, ...
Cancer Discovery, OF1-OF9, 2024
Mandates: Alex's Lemonade Stand
Available somewhere: 46
The genomic landscape of juvenile myelomonocytic leukemia
E Stieglitz, AN Taylor-Weiner, TY Chang, LC Gelston, YD Wang, T Mazor, ...
Nature genetics 47 (11), 1326-1333, 2015
Mandates: US National Institutes of Health
Genomic subtyping and therapeutic targeting of acute erythroleukemia
I Iacobucci, J Wen, M Meggendorfer, JK Choi, L Shi, SB Pounds, ...
Nature genetics 51 (4), 694-704, 2019
Mandates: US National Institutes of Health, National Health and Medical Research …
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome
AL Kennedy, KC Myers, J Bowman, CJ Gibson, ND Camarda, E Furutani, ...
Nature Communications 12 (1), 1334, 2021
Mandates: US National Institutes of Health
Genetic predispositions to childhood leukemia
E Stieglitz, ML Loh
Therapeutic advances in hematology 4 (4), 270-290, 2013
Mandates: US National Institutes of Health
Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia
E Stieglitz, CB Troup, LC Gelston, J Haliburton, ED Chow, KB Yu, ...
Blood, The Journal of the American Society of Hematology 125 (3), 516-524, 2015
Mandates: US National Institutes of Health
Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia
E Stieglitz, T Mazor, AB Olshen, H Geng, LC Gelston, J Akutagawa, ...
Nature communications 8 (1), 2127, 2017
Mandates: US National Institutes of Health
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML
A Yoshimi, ME Balasis, A Vedder, K Feldman, Y Ma, H Zhang, SCW Lee, ...
Blood, The Journal of the American Society of Hematology 130 (4), 397-407, 2017
Mandates: US Department of Defense, US National Institutes of Health
Phase II/III trial of a pre‐transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group
E Stieglitz, AF Ward, RB Gerbing, TA Alonzo, RJ Arceci, YL Liu, ...
Pediatric blood & cancer 62 (4), 629-636, 2015
Mandates: US National Institutes of Health
Activating mutations of RRAS2 are a rare cause of Noonan syndrome
Y Capri, E Flex, OHF Krumbach, G Carpentieri, S Cecchetti, C Lißewski, ...
The American Journal of Human Genetics 104 (6), 1223-1232, 2019
Mandates: German Research Foundation, Federal Ministry of Education and Research …
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus
PMK De Blank, AM Gross, S Akshintala, JO Blakeley, G Bollag, A Cannon, ...
Neuro-oncology 24 (11), 1845-1856, 2022
Mandates: US National Institutes of Health, Cancer Research UK, Brain Tumour Charity, UK
Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
MA Nix, K Mandal, H Geng, N Paranjape, YHT Lin, JM Rivera, ...
Cancer discovery 11 (8), 2032-2049, 2021
Mandates: US National Institutes of Health
International consensus definition of DNA methylation subgroups in juvenile myelomonocytic leukemia
M Schönung, J Meyer, P Nöllke, AB Olshen, M Hartmann, N Murakami, ...
Clinical Cancer Research 27 (1), 158-168, 2021
Mandates: US National Institutes of Health, German Research Foundation, Federal …
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B‐acute lymphoblastic leukemia
CF Contreras, CS Higham, A Behnert, K Kim, E Stieglitz, SK Tasian
Pediatric blood & cancer 68 (1), e28718, 2021
Mandates: US National Institutes of Health, Alex's Lemonade Stand
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study
CC Dvorak, P Satwani, E Stieglitz, MS Cairo, H Dang, Q Pei, Y Gao, ...
Pediatric blood & cancer 65 (7), e27034, 2018
Mandates: US National Institutes of Health
Molecular and phenotypic diversity of CBLmutated juvenile myelomonocytic leukemia
A Hecht, JA Meyer, A Behnert, E Wong, F Chehab, A Olshen, A Hechmer, ...
Haematologica 107 (1), 178, 2022
Mandates: US National Institutes of Health, German Research Foundation, V Foundation, USA
Matched targeted therapy for pediatric patients with relapsed, refractory, or high-risk leukemias: a report from the LEAP Consortium
Y Pikman, SK Tasian, ML Sulis, K Stevenson, TM Blonquist, ...
Cancer discovery 11 (6), 1424-1439, 2021
Mandates: US National Institutes of Health, National Institute of Health and Medical …
Fusion driven JMML: a novel CCDC88C–FLT3 fusion responsive to sorafenib identified by RNA sequencing
AK Chao, JA Meyer, AG Lee, A Hecht, T Tarver, J Van Ziffle, AK Koegel, ...
Leukemia 34 (2), 662-666, 2020
Mandates: US National Institutes of Health, Damon Runyon Cancer Research Foundation …
Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children
AJ de Smith, G Lavoie, KM Walsh, S Aujla, E Evans, HM Hansen, ...
Genes, Chromosomes and Cancer 58 (10), 723-730, 2019
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Publication and funding information is determined automatically by a computer program